Effects of glucosamine-chondroitin combination on synovial fluid IL-1beta, IL-6, TNF-alpha and PGE2 levels in internal derangements of temporomandibular joint
Damlar I, et al.
Published in Medicina Oral, Patologia Oral y Cirugia Bucal
Methodology
Randomised controlled trial of oral glucosamine-chondroitin versus control for 8 weeks in TMJ internal derangement, with synovial fluid cytokine and PGE2 assays plus pain and mouth-opening measures.
Key Findings
In 31 patients with internal derangement of the temporomandibular joint, oral glucosamine-chondroitin for 8 weeks reduced synovial fluid concentrations of IL-1beta, IL-6, TNF-alpha and PGE2 and improved pain and maximum mouth opening compared with the control group.
Conclusions
Glucosamine-chondroitin reduced inflammatory mediators in TMJ synovial fluid alongside symptom improvement, an interesting mechanistic signal from a very small trial.
Limitations
Tiny sample from a single centre, short 8-week duration, biomarker endpoints of uncertain clinical importance, invasive synovial sampling limiting participant numbers, and no long-term functional follow-up.
Supplements Studied
These results might suggest that glucosamine-chondroitin combination significantly increases the MMO and decreases the synovial fluid IL1 and IL6 levels in internal derangements of TMJ compared to tramadol.
These results might suggest that glucosamine-chondroitin combination significantly increases the MMO and decreases the synovial fluid IL1 and IL6 levels in internal derangements of TMJ compared to tramadol.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
University research funding (Turkey)
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.